Modeling lesion counts in multiple sclerosis when patients have been selected for baseline activity

Abstract

The number of new gadolinium-enhancing lesions discovered via magnetic resonance imaging is a well-established outcome for multiple sclerosis studies, especially Phase II Studies. Due to the high cost of magnetic resonance imaging scans, many investigators select participants for the presence of lesions. While this selection procedure is thought to improve the power of inferences, the effect of screening for baseline activity on parameter estimation and interval coverage has not yet been examined. The objective of this study was to investigate the performance of the negative binomial distribution for modeling lesion count data in multiple sclerosis when patients have been selected for activity on a baseline scan. We performed computer simulations to investigate the influence of the screening process on inferences made using a negative binomial model about treatment effects in two independent samples. We also demonstrate how the statistical properties of screening can be incorporated into trial design. We demonstrate that when the negative binomial distribution is used to model lesion counts, while screening for baseline activity improves point estimation, this practice also has the potential to decrease interval coverage and inflate the Type I error rate. For data that is to be modeled using a negative binomial distribution, screening for baseline activity can create a trade-off between cost effectiveness and a higher than desired false positive rate that must be carefully considered in planning Phase II trials.

Keywords

Multiple sclerosis MRI lesions negative binomial enrichment design

Get full access to this article

View all access options for this article.

References

McFarland HF , Frank JA , Albert PS , et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis . Ann Neurol 1992; 32: 758-766.

Sormani MP and Filippi M. Statistical issues related to the use of MRI data in multiple sclerosis . J Neuroimaging 2007; 17: 56S-59S.

Sormani MP , Bruzzi P. , Miller DH , Gasperini C. , Barkhof F. and Filippi M. Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: implications for clinical trials. J Neurol Sci 1999; 163: 74-80.

Sormani MP , Bruzzi P. , Rovaris M. , et al. Modelling new enhancing MRI lesion counts in multiple sclerosis . Mult Scler 2001; 7: 298-304.

van den Elskamp IJ , Knol DL , Uitdehaag BMJ and Barkhof F. The distribution of new enhancing lesion counts in multiple sclerosis: further explorations . Mult Scler 2009; 15: 42-49.

Aban IB , Cutter GR and Mavinga N. Inferences and power analysis concerning two negative binomial distributions with an application to MRI lesion counts data. Comput Stat Data Anal 2009; 53: 820-833.

Sormani MP , Bruzzi P. , Beckmann K. , et al. The distribution of magnetic resonance imaging response to interferonβ-1b in multiple sclerosis. J Neurol 2005; 252: 1455-1458.

Sormani MP , Bruzzi P. , Comi G. and Filippi M. The distribution of the magnetic resonance imaging response to glatiramer acetate in multiple sclerosis. Mult Scler 2005; 11: 447-449.

Sormani MP , Miller DH , Comi G. , et al. Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets. J Neurol Neurosurg Psychiatry 2001; 70: 494-499.

10.

Comi G. , Filippi M. , Wolinsky JS , and the European/ Canadian Glatiramer Acetate Study Group. European/ Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001; 49: 290-297.

11.

Temple RJ Special study designs: early escape, enrichment, studies in non-responders . Commun Stat Theory Meth 1994; 23: 499-531.

12.

Rudick RA , Cutter G. , Baier M. , et al. Use of the multiple sclerosis functional composite to predict disability in relapsing MS. Neurology 2001 ; 56: 1324-1330.

13.

Jacobs LK , Cookfair DL , Rudick RA , et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-294.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.23 MB

0.03 MB

0.23 MB